329 related articles for article (PubMed ID: 25041591)
1. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
Kaehler KC; Gutzmer R; Egberts F; Hauschild A
J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
[No Abstract] [Full Text] [Related]
2. Histologic Findings of Tumor Lysis in Advanced Basal Cell Carcinoma Treated With Vismodegib.
Powell EM; Stratton JS; Shendrik I; Blalock TW
Dermatol Surg; 2016 Jul; 42(7):904-7. PubMed ID: 27191782
[No Abstract] [Full Text] [Related]
3. Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment.
Feigenbaum L; Scott BL; Moye MS; Nijhawan RI
Dermatol Surg; 2017 Jul; 43(7):989-991. PubMed ID: 28002101
[No Abstract] [Full Text] [Related]
4. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
[No Abstract] [Full Text] [Related]
5. Vismodegib (Erivedge) for basal cell carcinoma.
Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
[No Abstract] [Full Text] [Related]
6. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
Cusack CA; Nijhawan R; Miller B; Henien M; Malat G; Doyle A; Abdelmalek M
JAMA Dermatol; 2015 Jan; 151(1):70-2. PubMed ID: 25337679
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib for the treatment of aggressive basal cell carcinoma in a patient unable to swallow pills.
Umanoff N; Sarbib K; Mulvaney M; Iorizzo L
Dermatol Surg; 2015 Mar; 41(3):433-5. PubMed ID: 25738448
[No Abstract] [Full Text] [Related]
8. Complete response of a locally advanced basosquamous carcinoma with vismodegib treatment.
Sahuquillo-Torralba A; Llavador-Ros M; Caballero-Daroqui J; Botella-Estrada R
Indian J Dermatol Venereol Leprol; 2019; 85(5):549-552. PubMed ID: 31389370
[No Abstract] [Full Text] [Related]
9. Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum.
Fife D; Laitinen MA; Myers DJ; Landsteiner PB
Pediatr Dermatol; 2017 Mar; 34(2):163-165. PubMed ID: 28297142
[TBL] [Abstract][Full Text] [Related]
10. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.
Iarrobino A; Messina JL; Kudchadkar R; Sondak VK
J Am Acad Dermatol; 2013 Jul; 69(1):e33-4. PubMed ID: 23768306
[No Abstract] [Full Text] [Related]
11. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib in the treatment of advanced BCC.
O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
14. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
Nayyar PM; Chang ALS; Sarin K; Ratner D
Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109
[No Abstract] [Full Text] [Related]
15. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
[No Abstract] [Full Text] [Related]
16. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
18. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
19. [Vismodegib in metastasized basal cell carcinoma].
Reinders MG; Dirix L; Mosterd K; van Doorn R
Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
[TBL] [Abstract][Full Text] [Related]
20. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
